Cancer Letters

Cancer Letters

Volume 345, Issue 2, 10 April 2014, Pages 174-181
Cancer Letters

Mini-review
Virus induced inflammation and cancer development

https://doi.org/10.1016/j.canlet.2013.07.030Get rights and content

Highlights

  • Tumourigenic viruses HBV, HCV, EBV, KSHV, HTLV and HPV all have confirmed roles in cancer initiation.

  • Inflammation as a result of chronic infection is mediated directly by viral proteins and indirectly as a result of viral replication.

  • HBV/HCV mediated inflammation plays a particularly prominent role in cancer initiation and progression, due to significant cell death and regeneration.

  • Inflammatory activation mediated directly by viral proteins is often a result of pathway overlap with growth/apoptosis signalling pathways (particularly NF-κB).

Abstract

Chronic inflammation as a result of viral infection significantly increases the likelihood of cancer development. A handful of diverse viruses have confirmed roles in cancer development and progression, but the list of suspected oncogenic viruses is continually growing. Viruses induce cancer directly and indirectly, by activating inflammatory signalling pathways and cytokines, stimulating growth of infected cells and inhibiting apoptosis. Although oncogenic viruses induce inflammation by various mechanisms, it is generally mediated by the MAPK, NFκB and STAT3 signalling pathways. This review will explore the unique mechanisms by which different oncogenic viruses induce inflammation to promote cancer initiation and progression.

Introduction

Viruses contribute significantly to cancer development worldwide, with up to 15% of human cancers attributed to chronic viral infection [1], [2]. Human papillomavirus (HPV) and hepatitis B virus (HBV) are the most significant contributors, but the list of tumourigenic viruses is much longer [1]. Epstein–Barr virus (EBV), human T-lymphotropic virus-I (HTLV-I), hepatitis C virus (HCV), Kaposi’s sarcoma herpesvirus (KSHV) and Merkel cell polyomavirus (MCV) all have confirmed roles in cancer induction, with a significantly longer list of viruses also suspected to play a role in tumourigenesis.

The acute inflammatory response to virus infection is an essential component of the antiviral response, inducing genes responsible for antiviral activity, immune cell recruitment and cell fate [3]. Unfortunately, excessive inflammation can arise during persistent infection and is generally damaging, having mutagenic effects on the host genome [4]. Chronic inflammation plays a role in a number of disease states, including diabetes, arthritis, Alzheimer’s disease, and over a longer period, cancer [5]. In the context of cancer development, chronic inflammation has been linked not only to tumourigenesis, but also to increased cell proliferation, survival, invasion, angiogenesis and metastasis [5], [6].

Tumourigenesis usually follows the accumulation of mutations in gene coding regions, resulting in uncontrolled cell growth. It is estimated that around 100 coding region mutations are present in a typical cancer genome, including 10–20 in genes actively contributing to oncogenesis [7], [8]. This implies that cancer development is usually a slow process, largely unaffected by acute infections which resolve. For this reason, viruses and bacteria with the potential to develop chronic infections are significantly over-represented among tumourigenic pathogens [9].

Cancer initiation during viral infection can generally be divided into two categories, based on the capacity of the virus to directly contribute to oncogenesis. Oncogenic viruses encode proteins that stimulate cell proliferation and/or interfere with cell apoptosis, and therefore play a direct role in carcinogenesis [10]. Most viral oncogenes target similar cell growth pathways to counteract the growth arrest that occurs in response to viral infection. Other viral oncogenes inhibit apoptosis and immune cell recognition, thus allowing ongoing viral replication.

Viral carcinogenesis can also occur indirectly, if chronic infection leads to oxidative stress and inflammation [10]. Cytokine secretion by the infected cell and surrounding tissues creates an inflammatory milieu which can promote cancer development, principally mediated by IL-1B, TNF-α and IL-6 [4], [11]. Inflammatory stimuli and direct effects of the virus activate signalling pathways responsible for cancer development, including NF-κB, STAT3 and the MAPKs [12], [13].

Inflammation alone can increase the oncogenic potential of a cell, but the combination of direct and indirect factors present during chronic viral infections explains the high rates of virus-associated cancers. This review will focus on the role of virus-induced inflammation in cancer development, highlighting the similarities and differences among oncogenic viruses.

Section snippets

Oncogenic viruses of the liver: HBV and HCV

HBV and HCV are both hepatotropic viruses which can establish persistent infection. HCV is unusual among oncogenic viruses, as it does not integrate into the host genome or demonstrate viral latency, yet sustains chronic infection in approximately 50–80% of untreated individuals [14]. Chronic HCV infection dramatically increases the likelihood of developing liver fibrosis (scarring) and steatosis (fat accumulation), with approximately 20% of patients developing cirrhosis, and 4% developing

Human T lymphotropic virus (HTLV-1)

Following an exhaustive worldwide search for a human retrovirus, HTLV-1 was identified in 1980 [60], [61]. HTLV-1 was the first retrovirus to be associated with human cancer, termed adult T-cell leukaemia (ATL) [62]. The HTLV-1 genome is positive sense RNA, which is reverse transcribed and integrates randomly into the genome of predominantly CD4+ T cells [63]. Following integration, clonal expansion of the infected T cells is induced by the viral trans-activator protein Tax, which interferes

EBV

EBV infects 90% of the world’s population, primarily as an asymptomatic infection in childhood [83]. Infection at a later stage (often adolescence) results in infectious mononucleosis, characterised by fever, pharyngitis and/or tonsillitis, and tender cervical lymphadenopathy [84]. EBV preferentially infects B lymphocytes, but has also been shown to infect other cells types, primarily epithelial cells [85], [86]. Following acute infection, EBV establishes latent infection in B lymphocytes,

KSHV

Like EBV, KSHV is a gamma herpes virus that usually remains latent as a nuclear episome, with occasional viral reactivation followed by lytic replication. However unlike EBV, KSHV is usually oncogenic only in immunosuppressed patients, either as a result of AIDS or following organ transplant [112], [113], [114]. KSHV is associated with the development of Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD) [115]. KSHV infection is more common in HIV

HPV

HPVs belong to the Papillomaviridae family, and are a diverse group of small non-enveloped dsDNA viruses. The ∼120 types of HPV identified to date can be subdivided based on their tissue tropism, infecting either cutaneous or internal mucosal surfaces [135]. The mucosal HPV types have further been divided based on their oncogenic potential, with low risk types generally causing benign genital warts, and high risk types associated with neoplasia and subsequent cancers. High risk HPV types 16 and

Conclusions

Chronic viral infection is increasingly being recognised as a leading cause of cancer worldwide. As well as the direct oncogenic role of some viruses, ongoing inflammation stimulated by chronic viral infections also contributes significantly to tumour formation. In addition to the viruses discussed above, mounting evidence now implicates other viruses in the development of human cancers. These include Merkel cell polyomavirus, which has been associated with the majority of Merkel cell

Conflict of interest

None.

References (178)

  • M.I. Radwan et al.

    Influence of transforming growth factor-beta1 and tumor necrosis factor-alpha genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients

    Cytokine

    (2012)
  • Y. Wang et al.

    Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection

    Hepatology

    (2003)
  • M. Okuda et al.

    Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein

    Gastroenterology

    (2002)
  • J.J. Ott et al.

    Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity

    Vaccine

    (2012)
  • R.C. Gallo

    Research and discovery of the first human cancer virus, HTLV-1

    Best Pract. Res. Clin. Haematol.

    (2011)
  • L.B. Cook et al.

    HTLV-1: persistence and pathogenesis

    Virology

    (2013)
  • T. Akagi et al.

    Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1

    Blood

    (1995)
  • Y. Furukawa et al.

    Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia

    Blood

    (2001)
  • M. Watanabe et al.

    Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia

    Blood

    (2005)
  • T. Zhao et al.

    Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB

    Blood

    (2009)
  • E.W. Harhaj et al.

    Human T cell leukemia virus type I Tax activates CD40 gene expression via the NF-kappa B pathway

    Virology

    (2005)
  • S. Tattermusch et al.

    HTLV-1 infection: what determines the risk of inflammatory disease?

    Trends Microbiol.

    (2012)
  • M.A. Epstein et al.

    Virus particles in cultured lymphoblasts from Burkitt’s lymphoma

    Lancet

    (1964)
  • N. Raab-Traub

    Novel mechanisms of EBV-induced oncogenesis

    Curr. Opin. Virol.

    (2012)
  • G. Khan

    Epstein–Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin’s lymphoma?

    Exp. Hematol.

    (2006)
  • D. Wang et al.

    An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells

    Cell

    (1985)
  • U. Zimber-Strobl et al.

    EBNA2 and Notch signalling in Epstein–Barr virus mediated immortalization of B lymphocytes

    Semin. Cancer Biol.

    (2001)
  • G. Mosialos et al.

    The Epstein–Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family

    Cell

    (1995)
  • E. Maggio et al.

    Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues

    Ann. Oncol.

    (2002)
  • U. Kapp et al.

    Hodgkin’s lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice

    Blood

    (1993)
  • N. Tedla et al.

    Abundant expression of chemokines in malignant and infective human lymphadenopathies

    Cytokine

    (1999)
  • D.M. Parkin

    The global health burden of infection-associated cancers in the year

    Int. J. Cancer

    (2002)
  • H. zur Hausen

    Viruses in human cancers

    Curr. Sci.

    (2001)
  • A. Mantovani

    Cancer: inflammation by remote control

    Nature

    (2005)
  • E.D. Pleasance et al.

    A small-cell lung cancer genome with complex signatures of tobacco exposure

    Nature

    (2010)
  • P.J. Stephens et al.

    Complex landscapes of somatic rearrangement in human breast cancer genomes

    Nature

    (2009)
  • P.S. Moore et al.

    Why do viruses cause cancer? Highlights of the first century of human tumour virology

    Nat. Rev. Cancer

    (2010)
  • Y. Ben-Neriah et al.

    Inflammation meets cancer, with NF-kappaB as the matchmaker

    Nat. Immunol.

    (2011)
  • Y. Fan et al.

    NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer

    Protein Cell

    (2013)
  • S.M. Kamal

    Acute hepatitis C: a systematic review

    Am. J. Gastroenterol.

    (2008)
  • A. Arzumanyan et al.

    Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma

    Nat. Rev. Cancer

    (2013)
  • J. Ferlay et al.

    Estimates of worldwide burden of cancer in 2008: GLOBOCAN

    Int. J. Cancer

    (2008)
  • L.R. Roberts et al.

    Hepatocellular carcinoma: molecular pathways and new therapeutic targets

    Semin. Liver Dis.

    (2005)
  • T. Suzuki et al.

    Molecular biology of hepatitis C virus

    J. Gastroenterol.

    (2007)
  • P. Simmonds

    Genetic diversity and evolution of hepatitis C virus – 15 years on

    J. Gen. Virol.

    (2004)
  • D. Ganem et al.

    Hepatitis B virus infection – natural history and clinical consequences

    N. Engl. J. Med.

    (2004)
  • C. Brechot

    Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms

    Gastroenterology

    (2004)
  • S.F. Wieland et al.

    Stealth and cunning: hepatitis B and hepatitis C viruses

    J. Virol.

    (2005)
  • S. Caldwell et al.

    The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology

    J. Gastroenterol.

    (2009)
  • J.R. Pekow et al.

    Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis

    Cancer

    (2007)
  • Cited by (0)

    View full text